Johnson & Johnson Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31)
Johnson & Johnson (JNJ) reported Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) of $306.00 million for the 3-month period ending 2018-07-01, per its 10-Q filed 2018-08-02.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet · last filed 2018-08-02
- Johnson & Johnson derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2018-07-01 was $306.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2017-07-02 was -$268.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2012-01-01 was -$395.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2011-10-02 was -$117.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2012 was -$500.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2011 was -$333.00M, a 976.32% decline from fiscal 2010.
- Johnson & Johnson derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2010 was $38.00M.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 3 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 6 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 9 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-07-01 | $306.00M 10-Q · filed 2018-08-02 | $156.00M 10-Q · filed 2018-08-02 | ||
| 2017-07-02 | -$268.00M 10-Q · filed 2018-08-02 | -$378.00M 10-Q · filed 2018-08-02 | ||
| 2012-01-01 | -$395.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$512.00M derived: sum of 2 quarters · filed 2012-02-23 | -$510.00M derived: sum of 3 quarters · filed 2012-02-23 | -$500.00M 10-K · filed 2012-02-23 |
| 2011-10-02 | -$117.00M 10-Q · filed 2011-11-08 | -$115.00M derived: sum of 2 quarters · filed 2011-11-08 | -$105.00M 10-Q · filed 2011-11-08 | -$158.00M derived: sum of 4 quarters · filed 2012-02-23 |
| 2011-07-03 | $2.00M 10-Q · filed 2011-08-09 | $12.00M 10-Q · filed 2011-08-09 | -$41.00M derived: sum of 3 quarters · filed 2012-02-23 | -$136.00M derived: sum of 4 quarters · filed 2012-02-23 |
| 2011-04-03 | $10.00M 10-Q · filed 2011-05-10 | -$43.00M derived: sum of 2 quarters · filed 2012-02-23 | -$138.00M derived: sum of 3 quarters · filed 2012-02-23 | -$296.00M derived: sum of 4 quarters · filed 2012-02-23 |
| 2011-01-02 | -$53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$148.00M derived: sum of 2 quarters · filed 2012-02-23 | -$306.00M derived: sum of 3 quarters · filed 2012-02-23 | -$333.00M 10-K · filed 2012-02-23 |
| 2010-10-03 | -$95.00M 10-Q · filed 2011-11-08 | -$253.00M derived: sum of 2 quarters · filed 2011-11-08 | -$280.00M 10-Q · filed 2011-11-08 | -$193.00M derived: sum of 4 quarters · filed 2011-11-08 |
| 2010-07-04 | -$158.00M 10-Q · filed 2011-08-09 | -$185.00M 10-Q · filed 2011-08-09 | -$98.00M derived: sum of 3 quarters · filed 2011-08-09 | -$278.00M derived: sum of 4 quarters · filed 2011-08-09 |
| 2010-04-04 | -$27.00M 10-Q · filed 2011-05-10 | $60.00M derived: sum of 2 quarters · filed 2011-05-10 | -$120.00M derived: sum of 3 quarters · filed 2011-05-10 | -$160.00M derived: sum of 4 quarters · filed 2011-05-10 |
| 2010-01-03 | $87.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | -$93.00M derived: sum of 2 quarters · filed 2011-02-25 | -$133.00M derived: sum of 3 quarters · filed 2011-02-25 | $38.00M 10-K · filed 2011-02-25 |
| 2009-09-27 | -$180.00M 10-Q · filed 2010-11-10 | -$220.00M derived: sum of 2 quarters · filed 2010-11-10 | -$49.00M 10-Q · filed 2010-11-10 | |
| 2009-06-28 | -$40.00M 10-Q · filed 2010-08-11 | $131.00M 10-Q · filed 2010-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |